Analysis of Anxiety and Depression Among Elderly People
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Aug 22, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
China is one of the countries with the fastest aging population in the world. With the rapid aging of the population, there is an urgent need to build cities and communities into age-friendly cities and communities that facilitate the lives of the elderly and continue to make meaningful contributions to society. Various parts of our country are also actively exploring and constructing elderly care models with local characteristics, and an aging social environment of "respecting, loving and enjoying the elderly" is gradually being built.
However, due to the gradual decline of various organ ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) ≥65 years old, lived in a nursing home for ≥1 year.
- • 2) Not limited to men and women.
- Exclusion Criteria:
- • Those who cannot cooperate to complete the questionnaire, such as senile dementia, those who cannot express themselves after traumatic brain injury
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported